Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Selpercatinib, sold under the brand name Retevmo among others, is a targeted medication for the treatment of cancers in people whose tumors have an alteration (mutation or fusion) in a specific gene (RET which is short for "rearranged during transfection"). Before beginning treatment, the identification of a RET gene alteration must be determined using laboratory testing. Selpercatinib is taken by mouth.
Read the full article on WikipediaLocally advanced or metastatic non-small cell lung cancer Clinical criteria: The condition must have evidence of rearranged during transfection (RET) gene fusion in tumour material - this evidence has been obtained prior to commencing treatment with this drug, AND Patient must have a World Health Organisation (WHO) Eastern Cooperative Oncology Group (ECOG) performance status score of no higher than 2 at treatment initiation, AND The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this PBS indication, AND Patient must be initiating treatment with this drug; OR Patient must be continuing treatment with this drug, with an absence of further disease progression while being treated with this drug. Medical practitioners must prescribe the appropriate quantities of appropriate strength(s) to provide sufficient drug, based on the weight of the patient, adequate for 4 weeks per dispensing, according to the specified dosage in the approved Therapeutic Goods Administration (TGA) Product Information (PI). A separate authority prescription form must be completed for each strength requested.
Working under the parallel aged-care framework? Aged-care equivalent →